Rhumbline Advisers Makes New Investment in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Rhumbline Advisers bought a new position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,291 shares of the company’s stock, valued at approximately $123,000.

Separately, Bank of New York Mellon Corp purchased a new position in shares of Gyre Therapeutics in the second quarter worth about $218,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Trading Down 1.7 %

Shares of NASDAQ GYRE opened at $12.54 on Tuesday. Gyre Therapeutics, Inc. has a 52 week low of $4.80 and a 52 week high of $30.40. The business’s 50 day moving average price is $12.75 and its 200 day moving average price is $13.59.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings data on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The business had revenue of $25.23 million during the quarter. On average, sell-side analysts expect that Gyre Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.